U.S. Cannabis Policy Shift: Implications for Europe and SYNBIOTIC

The U.S. cannabis market is experiencing significant changes following an Executive Order by President Trump. This order, signed on December 18, 2025, reclassifies marijuana from Schedule I to Schedule III, altering its status at the federal level. This move, described by Trump as "common sense," is expected to benefit medical cannabis use without legalizing recreational use.

This policy shift has been received positively by companies as it may ease tax and banking issues. However, some conservative groups express concerns regarding public health and youth consumption. The order is particularly noteworthy ahead of the 2026 midterm elections, potentially appealing to younger voters.

Globally, these developments could influence European markets, especially Germany. For SYNBIOTIC, an international player in the medical cannabis sector, the changes in U.S. policy could enhance opportunities for growth and alignment in regulatory frameworks.